Earticle

초록

영어

Background: Rare digestive system cancers, including cholangiocarcinoma and other low-incidence malignancies, have limited treatment options and often harbor alterations in the RAS–RAF–MEK–ERK pathway. MEK inhibitors have shown preclinical activity, but clinical efficacy remains unclear. This systematic review and meta-analysis evaluated the therapeutic impact of MEK inhibitors in rare digestive cancers. Methods: Following PRISMA guidelines, MEDLINE, Cochrane Library, and ClinicalTrials. gov were searched for randomized phase II or III trials investigating MEK inhibitors in rare cancers. Data extraction and riskof- bias assessment were performed independently by two reviewers. Pooled odds ratios (OR) were calculated using randomor fixed-effects models depending on heterogeneity. Results: Total of 522 records screened, four phase II trials (n=210) met inclusion criteria, evaluating selumetinib, trametinib, and cobimetinib. MEK inhibitor therapy did not improve ORR compared with control (OR 0.93; 95% CI 0.35-2.48; I2=0%). No complete responses were reported. Most studies demonstrated high performance and detection bias due to open-label design, and overall certainty of evidence was rated low. Conclusions: MEK inhibitors showed limited clinical activity in rare digestive system cancers and the current evidence remains insufficient to confirm their efficacy as either monotherapy or in combination therapy. Future trials should incorporate biomarker-selected populations and rational combination strategies to overcome pathway resistance.

목차

ABSTRACT
Materials and Methods
Literature searching
Eligibility criteria and abstract screening
Data extraction and quality assessment
Data analysis
Results
Results of the literature review
Characteristics of the Included Studies
Response rate of rare cancer patients with MEK inhibitors
Risk of bias assessment and quality of evidence of includedstudies
Discussion
Conclusion
Conflict of Interest
References

키워드

저자

• Yunjung Choi [ College of Pharmacy, Inje University/Inje Institute of Pharmaceutical Sciences and Research, Inje University, Gimhae 50843, Republic of Korea ]
• Aya Nasr Mamdouh Hussein [ College of Pharmacy, Inje University/Inje Institute of Pharmaceutical Sciences and Research, Inje University, Gimhae 50843, Republic of Korea ]
• Heeyoung Lee [ College of Pharmacy, Inje University/Inje Institute of Pharmaceutical Sciences and Research, Inje University, Gimhae 50843, Republic of Korea ] Corresponding Author

참고문헌

발행기관

간행물

표지보기 관심저널 등록

• 간행물명

  한국임상약학회지 [Korean Journal of Clinical Pharmacy]

• 간기

  계간

• pISSN

  1226-6051

• 수록기간

  1991~2026

• 등재여부

  KCI 등재

• 십진분류

  KDC 518 DDC 615